First COVID-19 vaccine trial starts in Adelaide

Human trials of a potential COVID-19 vaccine developed at Flinders have commenced in South Australia.

The Phase 1 trial at the Royal Adelaide Hospital will test a promising new COVID-19 vaccine candidate, called COVAX-19®, and is described as the first human trial of a SARS-CoV-2 (COVID-19) vaccine in the Southern Hemisphere.

The targeted vaccine, developed by Vaxine Pty Ltd and Flinders University researchers, will provide initial safety and immune response data on 40 healthy participants aged between 18 and 65 years who have been pre-screened. The participants will receive two doses, three weeks apart, of the new vaccine or a placebo injection and will then have blood tests to measure protective antibody and T-cell responses induced by the vaccine.

The World Health Organization lists more than 120 COVID-19 vaccine projects in either preclinical and early human clinical trials, with several others in Australia also closing in on possible human testing.

Flinders University Professor Nikolai Petrovsky, chairman and research director of Vaxine, says the COVAX-19® candidate is based on the company’s recombinant spike protein approach.

“The vaccine was developed from Vaxine’s earlier SARS coronavirus vaccine approach, which combines with Vaxine’s non-inflammatory Advax-CpG55.2 adjuvants,” Professor Petrovsky says.

“Past experience with adenovirus-based vaccines has shown disappointing protection and high toxicity and DNA and mRNA type vaccines have their own problems, including being unproven technologies that may still turn out to be poorly scaleable or have unexpected side effects.

“Low immunogenicity of adenovirus, DNA and mRNA technologies in particular could be a major problem when it comes to coronavirus vaccines, where immunity will need to be strong and long-lasting,” he says.

The first volunteer in the SA trial, Ian Tindall, receives the new vaccine at the Royal Adelaide Hospital this week.

“Most of these vaccine technologies are unable to benefit from adjuvants, which are the key turbochargers that are bolted onto protein-based vaccines to dramatically enhance their effectiveness.”

The vaccine model was developed with artificial intelligence (AI), and received support from the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health under NIAID Contracts HHSN272200800039C, HHSN272201400053C, and HHSN27221800024C.

Professor Petrovsky says long-term funding is required to build a robust pandemic vaccine platform and advance it into human trials.

“Pandemic vaccine development is of paramount public health importance. Research in this area should not be something you can turn on and off like a tap.”

Principal Investigator on the vaccine project, Flinders University Professor David Gordon, a microbiologist and infectious diseases physician with SA Pathology, says the trial is the first of several planned and involves testing the safety and immune responses to the vaccine.

“This COVID-19 vaccine has already shown promising results in animal models, so it is exciting to take this national breakthrough to human trials in Adelaide,” Professor Gordon says.

“The development of antibodies and other immune responses will be determined two weeks after the second injection, so the results of the first trial will available in around two months’ time.”

Professor Nikolai Petrovsky in the research laboratory at Flinders University.

Dr Pravin Hissaria, Clinical Immunologist from Royal Adelaide Hospital, says the trial participants’ involvement is a vital component of the medical research to find a vaccine.

“Now, members of the public have stood up to be among the first people in the world to receive a trial vaccine. Their actions could help us find a permanent solution to this devastating global pandemic,” he says.

/Public Release. The material in this public release comes from the originating organization and may be of a point-in-time nature, edited for clarity, style and length. View in full here.